PredicineBEACON
Use
PredicineBEACON is a personalized, actionable Minimal Residual Disease (MRD) detection assay designed to offer ultra-sensitive MRD detection capabilities. It enables comprehensive monitoring of disease progression or recurrence in cancer patients by tracking up to 250 personalized mutations, including fusions, and detecting 500 actionable mutations. The assay is not limited by baseline tissue sample availability and can be performed using blood, urine, or tissue samples. This flexibility enhances its utility in clinical settings where baseline samples may be unavailable or limited.
Special Instructions
Not provided.
Limitations
While PredicineBEACON provides high sensitivity in detecting MRD, the assay's performance may vary depending on the quality and quantity of the sample provided. It requires a minimum input of 30ng cfDNA. The assay's accuracy in detecting mutations is contingent upon the available sample and its condition. In settings where very low mutation frequencies exist, detection limits are set to a sensitivity of up to 0.0025% tumor fraction.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
6 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
4-10 mL
Minimum Volume
Not provided
Collection Instructions
CLIA-validated assay requires two tubes of 10mL blood.